Bookmark Article
Eli Lilly’s weight-loss drug tirzepatide, sold as Mounjaro and Zepbound, is no longer in shortage in the US, according to the FDA. The drugmaker has resolved the shortage by increasing production and working to meet demand, along with rival drugmaker Novo Nordisk. The market for these drugs is expected to grow significantly, prompting both companies to expand production and invest in new facilities.
Full Article
